Sarah Bonnet

Sarah Bonnet

Auto-generated profile, based on publicly available information

Sarah Bonnet

Service d’Hématologie Clinique, CHU de Montpellier, Montpellier, France

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 December 2024 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
PCPatrice Chevallier
Patrice Chevallier
TLThibaut Leguay
Thibaut Leguay
MDMarc Delord
Marc Delord
CSCyril Salek
Cyril Salek
RKRathana Kim
Rathana Kim
E(European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL)
European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL)
PURPOSE: The use of inotuzumab ozogamicin (InO), a conjugated anti-CD22 monoclonal antibody, is becoming a promising frontline treatment for older patients with ALL. PATIENTS AND METHODS: EWALL-INO is an open-label prospective multicenter phase II trial (ClinicalTrials.gov identifier: NCT03249870 ). Patients age 55 years and older with newly diagnosed CD22 + Philadelphia chromosome–negative (Ph–) B-cell precursor (BCP) ALL were eligible. After a prephase, a first induction consisting of vincristine, dexamethasone, and three injections of InO (0.8 mg/m 2 day 1, 0.5 mg/m 2 day 8/day 15) was followed by a second induction combining cyclophosphamide, dexamethasone, and two injections of InO (0.5 mg/m 2 day 1/day 8). Responders received up to six cycles of chemotherapy consolidation and 18-month chemotherapy maintenance. Allotransplant was allowed after three consolidations. The primary end point was 1-year overall survival (OS). RESULTS: Between December 2017 and March 2022, 131 patients (median age 68 years) were included. Three patients died during induction 1 (n = 130), two from multiple organ failure and one from hemorrhage, and none during induction 2 (n = 120). After induction 2, 90% of the patients achieved complete remission (CR) or CR with incomplete platelet recovery (CRp) and 80% had measurable residual disease (MRD2) <10 −4 . Among responders (n = 119), 47 relapsed and 14 died in CR/CRp. One-year OS, relapse-free survival (RFS), and cumulative incidence of relapse (CIR) rates were 73.2%, 66%, and 25%, respectively. High-risk cytogenetics and lower CD22 expression (<70%) were associated with worse OS, while both high-risk cytogenetics and MRD2 ≥10 −4 were associated with lower RFS and higher CIR. The 10 allotransplanted patients had very favorable outcomes (90% 2-year OS/RFS and no relapse). Only one nonfatal sinusoidal obstructive syndrome was documented during the study. CONCLUSION: Our results support InO's use in first-line regimens for older patients with CD22 + Ph– BCP-ALL.

20 June 2024 in American Journal of Hematology
Verified
Journal Article
Open access
SGSylvain Garciaz
Sylvain Garciaz
PDPierre‐Yves Dumas
Pierre‐Yves Dumas
SBSarah Bertoli
Sarah Bertoli
DSDavid Sallman
David Sallman
JDJustine Decroocq
Justine Decroocq
CRChristian Récher
Christian Récher
Venetoclax‐azacitidine is the standard of treatment for unfit acute myeloid leukemia patients. In the VIALE‐A study, treatment was given until progression but there are no data on its optimal duration for responding patients who do not tolerate indefinite therapy. We retrospectively analyzed the outcome of patients who discontinued venetoclax or venetoclax‐azacitidine due to poor tolerance. Sixty‐two newly diagnosed (ND) AML patients and 22 patients with morphological relapse or refractory AML were included. In the ND cohort (n = 62), 28 patients stopped venetoclax and azacitidine and 34 patients continued azacitidine monotherapy. With a median follow‐up of 23 months (IQR, 20–32), median overall survival and treatment‐free survival were 44 (IQR, 16‐NR) and 16 (IQR, 8–27) months, respectively. Patients who stopped both treatments and those who continued azacitidine monotherapy had the same outcomes. Negative minimal residual disease was associated with a 2‐year treatment‐free survival of 80%. In the RR cohort (n = 22), median overall survival and treatment‐free survival were 19 (IQR, 17–31) and 10 (IQR, 5‐NR) months, respectively. Prior number of venetoclax‐azacitidine cycles and IDH mutations were associated with increased overall survival. The only factor significantly impacting treatment‐free survival was the number of prior cycles. This study suggests that patients who discontinued treatment in remission have favorable outcomes supporting the rationale for prospective controlled trials.

13 February 2025 in Blood Advances
Verified
Journal Article
Open access
SKSabine Khalife-Hachem
Sabine Khalife-Hachem
APArnaud Pagès
Arnaud Pagès
EAElie Akoury
Elie Akoury
SBSarah Bonnet
Sarah Bonnet
RBRudy Birsen
Rudy Birsen
DGDavid Ghez
David Ghez

19 September 2018 in The Breast Journal
Verified
Journal Article
Open access
PDF file
SBSarah E. Bonnet
Sarah E. Bonnet
JKJustine K. Kang-Chapman
Justine K. Kang-Chapman
KBKaila A. Buckley
Kaila A. Buckley
XCXiaoyan Cui
Xiaoyan Cui
VGValerie Grignol
Valerie Grignol
JHJeffrey R. Hawley
Jeffrey R. Hawley

15 July 2025 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
RHRawan Hallal
Rawan Hallal
MTMarion de Toledo
Marion de Toledo
DTDenis Tempé
Denis Tempé
RBRayane Berrahouane
Rayane Berrahouane
SZSara Zemiti
Sara Zemiti
GBGuillaume Bossis
Guillaume Bossis
NK cells can play a significant role in the antitumoral immune response. In patients with acute myeloid leukemia (AML), NK cells are, however, often found in low numbers and exhibit poor activity, contributing to leukemic progression. Allogenic NK cells are emerging as promising cellular therapies for hematologic cancer treatment. New strategies are however required to both reactivate NK cells in patients with AML and enhance the antitumor activity of transplanted NK cells. In this study, we demonstrate that targeting SUMOylation, a protein posttranslational modification, activates NK cells from both healthy donors and patients with AML. Subasumstat (TAK-981), a first-in-class inhibitor of SUMOylation used in phase I/II clinical trials, enhances NK cell degranulation, secretion of inflammatory cytokines (IFN-γ, TNF-α, and FasL), and cytotoxicity against AML cells. In vivo, TAK-981 improves the anti-leukemic efficacy of ex vivo expanded cord blood NK cells in leukemia-bearing mice. One early effect of TAK-981 is to specifically increase the accessibility and activation of cis-regulatory regions of IFN-I pathway genes and induce their transcription. TAK-981–induced secretion of IFN-β, mostly by NK cells and myeloid cells, is required for NK cell activation. Surprisingly, IFNB1 induction does not require its best-characterized activators MDA5, cGas, and IFN response factor-1, -3, and -7. Altogether, this suggests that targeting SUMOylation activates a noncanonical IFN-I pathway, which enhances the anti-leukemic potential of NK cells.

2 November 2023 in European Journal of Haematology
Verified
Journal Article
Open access
SBSarah Bonnet
Sarah Bonnet
SCSerge Carillo
Serge Carillo
BLBaptiste Legrand
Baptiste Legrand
BBBarbara Burroni
Barbara Burroni
TLThierry Lavabre‐Bertrand
Thierry Lavabre‐Bertrand
CHCharles Herbaux
Charles Herbaux
We describe the case of a patient with extreme thrombocytosis whose evolution was rapidly fatal. No cause of secondary thrombocytosis was found. There was no sign of myelofibrosis but the megakaryocytes were small and dysplastic. The patient presented a calreticulin (CALR) variant in exon 3 (C105S), as well as concomitant mutations of ASXL1, U2AF1, and EZH2. This variant of CALR has never been described before, and after sorting, all identified mutations were found in myeloid cells but not in lymphoid cells. Therefore, the diagnosis of a frontier case of myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) was made. A treatment with hydroxycarbamide was started because of a high risk of thrombosis. Upon worsening of the hematological status two new mutations appeared, SETBP1 and ETV6, and the CALR mutation was still detectable, as well as the three other mutations found in the chronic stage. Our results show that this variant could contribute to MDS/MPN pathogenesis in that patient.